TScan Therapeutics Inc
NASDAQ:TCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
TScan Therapeutics Inc
NASDAQ:TCRX
|
US |
|
Advanced Micro Devices Inc
NASDAQ:AMD
|
US |
|
K
|
Kbc Groep NV
DUS:KDB
|
BE |
|
D
|
Dave and Buster's Entertainment, Inc
SWB:9DB
|
US |
|
Mediobanca Banca di Credito Finanziario SpA
MIL:MB
|
IT |
|
Nuvectis Pharma Inc
NASDAQ:NVCT
|
US |
Intrinsic Value
Is TCRX undervalued or overvalued?
See the intrinsic value estimate for TScan Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What TScan Therapeutics Does
TScan Therapeutics is a biotechnology company that develops T cell receptor, or TCR, therapies for cancer. Its main idea is to find tumor targets that are shown on cancer cells and then design engineered T cells that can recognize and attack those cells. The company is still focused on development, so it does not sell a broad catalog of medicines like a traditional drugmaker; it works on building future cancer treatments that can move through clinical testing.
- Headquarters
- United States of America US
- Employees
- 142
- IPO date
- Jul 16, 2021
Earnings Waterfall
TScan Therapeutics Inc
The intrinsic value for TScan Therapeutics Inc (TCRX) under the Base Case is hidden USD.
Compared with the current market price of 0.17605 USD, the stock appears hidden.